Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose to conduct a randomised phase III trial evaluating a maintenance
strategy comparing hepatic arterial injection of Yttrium-90 resin microspheres plus
continuing simplified chemotherapy with/without targeted therapy versus continuing simplified
chemotherapy with/without targeted therapy alone for patient with dominant or exclusive and
unresectable liver mCRC controlled after 3-6 months of chemotherapy induction.